Early detection of ovarian cancer and response prediction: TEP and ctDNA study.

Early detection of ovarian cancer and response prediction: TEP and ctDNA study. - TEP ctDNA study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50170

Enrollment

200

Registered

2019-04-11

Start date

2019-07-15

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian tumor ovarium cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who are suspected of having ovarian cancer, patients who are diagnosed with ovarian cancer, and patients with ovarian cysts of which it is unknown whether it is benign or malignant and who receive either surgery with definitive pathology or follow up.

Exclusion criteria

Exclusion criteria: Woman diagnosed with any type of cancer besides ovarian cancer. Previous intra-abdominal malignancies in the history

Design outcomes

Primary

Measure	Time frame
To distinguish benign ovarium lesions from early cancer lesions, based upon their ctDNA en platelet RNA profile. To evaluate the accuracy of prediction response of ovarian carinomas on therapy.	—

Secondary

Measure	Time frame
Evaluate the diagnostic accuracy of ctDNA and platelet RNA profiling in detecting early-stage ovarium cancer compared to healthy controls; Evaluate the diagnostic accuracy of ctDNA and platelet RNA profiling in detecting early-stage ovarium cancer compared to stage IV ovarium cancer; Evaluate the accuracy of ctDNA and platelet RNA profiling in differentiating between ovarium cancer and other tumor types.	—

Measure

Time frame

Evaluate the diagnostic accuracy of ctDNA and platelet RNA profiling in detecting early-stage ovarium cancer compared to healthy controls; Evaluate the diagnostic accuracy of ctDNA and platelet RNA profiling in detecting early-stage ovarium cancer compared to stage IV ovarium cancer; Evaluate the accuracy of ctDNA and platelet RNA profiling in differentiating between ovarium cancer and other tumor types.

—

Countries

Netherlands

Outcome results